Glaxo Zantac exclusivity extension runs through Aug. 29, unless Genpharm or Geneva win suits.
GLAXO EXTENDED ZANTAC EXCLUSIVITY WILL RUN THROUGH AUG. 29 unless Genpharm or Geneva can prevail in separate litigation surrounding the effort to launch a generic version of ranitidine. Genpharm has been awarded exclusivity for generic ranitidine through Aug. 29, but cannot come to market until it prevails in litigation against Glaxo by proving that its form 1 ranitidine does not violate Glaxo's form 2 ranitidine patent, expiring in 2002. Geneva has filed a motion with the Fourth Circuit Court of Appeals for an injunction that all eligible manufacturers can bring generic ranitidine to market July 26; Geneva and Novopharm could market ranitidine if the court rules in its favor.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth